Drug persistence with rivaroxaban therapy in atrial fibrillation patients - Results from the Dresden non-interventional oral anticoagulation registry

Europace

Volumn 17, Issue 4, 2015, Pages 530-538

  Beyer Westendorf, Jan ^a   Förster, Kati ^a   Ebertz, Franziska ^a   Gelbricht, Vera ^a   Schreier, Thomas ^a   Göbelt, Maria ^a   Michalski, Franziska ^a   Endig, Heike ^a   Sahin, Kurtulus ^b   Tittl, Luise ^a   Weiss, Norbert ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Institute for Clinical Research and Statistics   (Germany)

Author keywords

Anticoagulants; Atrial fibrillation; NOAC; Persistence; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; HEPARIN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; ECZEMA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAIR LOSS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMATURIA; HEMOPTYSIS; HUMAN; KAPLAN MEIER METHOD; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; REGISTER; SIDE EFFECT; SINUS RHYTHM; SKIN BRUISING; TRANSIENT ISCHEMIC ATTACK; VERTIGO; ATRIAL FIBRILLATION; DRUG USE; GERMANY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; STROKE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UTILIZATION;

AGED; ATRIAL FIBRILLATION; DRUG UTILIZATION REVIEW; FACTOR XA INHIBITORS; FEMALE; GERMANY; HUMANS; MALE; PREVALENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; RIVAROXABAN; STROKE; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84926638672     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu319     Document Type: Article

References (22)

1. AgenoW, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e44S-88S.
2. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008;6: 1500-6.
3. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.
4. De Breucker S, Herzog G, Pepersack T. Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. Drugs Aging 2010;27: 807-13.
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-91.
6. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C,Werth S et al. Periinterventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014;35:1888-96.
7. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-62.
8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-51.
9. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981-92.
10. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369: 2093-104.
11. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8.
12. Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25.
13. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010;3:624-31.
14. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Juurlink DN. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012;172:1687-9.
15. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008; 29:1181-9.
16. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
17. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012;14:1385-413.
18. Nelson WW, Choi JC, Vanderpoel J, Damaraju CV, Wildgoose P, Fields LE et al. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. Am J Cardiol 2013;112:509-12.
19. MelamedOC, Horowitz G, Elhayany A, Vinker S. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 2011;17:232-7.
20. Grand'Maison A, CharestAF, GeertsWH.Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 2005;5:291-305.
21. Kleinow ME, Garwood CL, Clemente JL, Whittaker P. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm 2011;17:523-30.
22. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009;20:912-21.